Overview
- Axon fell 8.21% to a 52-week low of $396.41 on Tuesday, leaving the stock about 55% below its recent high.
- Shares rebounded Wednesday by about 6% during a broad market rally, as Goldman Sachs kept a Buy rating but lowered its target to $625.
- Investors are watching an upcoming court hearing over lawsuits that challenge Axon’s planned $1.3 billion Scottsdale campus, a case that could reshape its spending plans.
- Analyst calls are split, with Bank of America cutting its target to $700, RBC to $735, and Craig-Hallum to $820, while TD Cowen raised its target to $950 on strong bookings and guidance.
- Axon reported about 53% Q4 bookings growth and issued fiscal 2026 revenue guidance above forecasts, yet InvestingPro still flags the shares as overvalued and the stock is down 27% this year.